Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 4/20 | 0.52 |
| ▸ | LAP3 | P28838 | 2/20 | 0.49 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.47 |
| ▸ | S1PR2 | O95136 | 6/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 6/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11799989 | 0.97 | FDPS (0.52) | FDPSLAP3GGPS1S1PR2S1PR1 | |
| SCHEMBL16697100 | 0.84 | LPAR3 (0.42) | FDPSLAP3GGPS1MMP1MMP2 | |
| SCHEMBL10928634 | 0.82 | PLA2G4A (0.39) | FDPSLAP3MMP1MMP2MMP3 | |
| SCHEMBL16697061 | 0.82 | LPAR3 (0.40) | FDPSLAP3GGPS1MMP1MMP2 | |
| SCHEMBL10928628 | 0.81 | FDPS (0.40) | FDPSLAP3GGPS1MMP1MMP2 | |
| SCHEMBL16697383 | 0.79 | FDPS (0.47) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL9487038 | 0.78 | FDPS (0.59) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL2023917 | 0.78 | FDPS (0.59) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL9841018 | 0.78 | FDPS (0.59) | FDPSLAP3S1PR2S1PR1S1PR3 | |
| SCHEMBL3470937 | 0.78 | FDPS (0.59) | FDPSLAP3S1PR2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022117948-A1 | METHOD FOR SELECTIVELY RECOVERING RARE EARTH METALS AND URANIUM(VI) FROM AN AQUEOUS SOLUTION OF PHOSPHORIC ACID | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2022-06-09 | — | — | WO | claimed |
| WO-2022117948-A1 | METHOD FOR SELECTIVELY RECOVERING RARE EARTH METALS AND URANIUM(VI) FROM AN AQUEOUS SOLUTION OF PHOSPHORIC ACID | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2022-06-09 | — | — | WO | disclosed |
| US-9441285-B2 | Bifunctional compounds useful as ligands of uranium (VI), methods of synthesising same and uses thereof | AREVA MINES (FR) | 2016-09-13 | — | — | US | disclosed |
| US-20150133688-A1 | BIFUNCTIONAL COMPOUNDS USEFUL AS LIGANDS OF URANIUM (VI), METHODS OF SYNTHESISING SAME AND USES THEREOF | AREVA MINES (FR) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133688-A1 | BIFUNCTIONAL COMPOUNDS USEFUL AS LIGANDS OF URANIUM (VI), METHODS OF SYNTHESISING SAME AND USES THEREOF | URB2, CHRM2, C1S | FDPS 2645/4885LAP3 2240/4885GGPS1 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.